An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Negative Breast Cancer and Research of Biomarkers of Activity and Efficacy of Afatinib

Trial Profile

An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Negative Breast Cancer and Research of Biomarkers of Activity and Efficacy of Afatinib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Afatinib (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 05 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top